AMG 334 CGRP antibody for migraine: time to celebrate?

• Published in: Lancet neurology Vol. 15; no. 4; pp. 347 - 349
• Main Authors: Ramos, Marta L, Pascual, Julio
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.04.2016; Elsevier Limited
• Subjects: Advantages; Analgesics; Antibodies, Monoclonal - pharmacology; Clinical trials; Female; Headaches; Humans; Immunoglobulins; Immunologic Factors - pharmacology; Ligands; Male; Migraine; Migraine Disorders - prevention & control; Neurology; Outcome Assessment (Health Care); Peptides; Receptors, Calcitonin Gene-Related Peptide - antagonists & inhibitors
• ISSN: 1474-4422; 1474-4465
• DOI: 10.1016/S1474-4422(16)00040-5

Target Optimum dose Route of administration Dosing Inclusion and exclusion criteria Migraine days at baseline Decrease in migraine days versus placebo (95% CI) ALD 4036 CGRP ligand 1000 mg Intravenous Once 5-15 migraine days per 4 weeks at baseline; preventive treatments and analgesic overuse not allowed 8·4-8·8 1 (0·1-2) LY29517427 CGRP ligand 150 mg Subcutaneous Every 2 weeks for 12 weeks 4-14 migraine days per 4 weeks at baseline; preventive treatments and analgesic overuse not allowed 6·7-7 1·2 (0·6-1·9) TEV-481258 CGRP ligand 225 mg Subcutaneous Three doses, one dose injected every 4 weeks 8-14 migraine days at baseline; preventive treatments allowed; patients excluded if failure with at least three preventive treatments; triptans as needed allowed; use of less than four opioids and barbiturates allowed per month 11·3-11·5 2·81 (1·55-4·07) AMG 3345 CGRP receptor 70 mg Subcutaneous Three doses, one dose injected every 4 weeks 4-14 migraine days at baseline; patients excluded if failure with more than two preventive treatments; preventive treatments not allowed 8·6-8·9 1·1 (0·2-2·1) Table Calcitonin gene-related peptide (CGRP) antibodies tested in patients with episodic migraine